Our vision

is to create value by implementing a groundbreaking approach to Biomed research that actively promotes knowledge synergies, enhance accelerated innovation, thus providing an urgently needed response to the declining productivity, scope and quality of innovation in the Pharma industry.

About Us

BioLight Life Sciences Investments invests in, manages and commercializes biomedical innovations grouped around defined medical conditions. The two current medical conditions are ophthalmology, via 100% ownership of XLVision Sciences, and cancer diagnostics via a 46% controlling ownership of Micromedic Technologies (TASE: MCTC). The ophthalmic technologies include IOPtiMate™, a laser-based non-invasive surgical treatment for glaucoma; TeaRx™, a point-of-care multi-parameter diagnostic test for dry-eye syndrome; Eye-D®, a controlled release drug-delivery insert platform and a new technology a drug-delivery platform for the improvement of ocular molecule transmission; and OphRx, a drug delivery technology platform for ocular uses. The cancer diagnostic activities include tests that are designated for bladder, cervical, multiple myeloma and other cancers.

Leading key investors, holding about 36% of BioLight’s issued and outstanding shares, are Mr. Israel Makov, Chairman of Sun Pharmaceuticals, former CEO and President of Teva Pharmaceuticals and former Chairman of Given Imaging, Mr. Dilip Shanghvi, founder of Sun Pharmaceuticals, India’s largest pharmaceutical company, and Mr. Dan Oren, founder and CEO of Dexcel Pharma, the second-largest pharmaceutical manufacturer in Israel.

BioLight is a public company traded on the Tel Aviv Stock Exchange (BOLT) and on the OTCQX (BLGTY).

Company Presentation